Abstract 268P
Background
In early breast cancer, residual disease after neoadjuvant chemotherapy is considered an important prognostic factor, especially for triple-negative breast cancer (TNBC) and HER2-positive patients. The CREATE-X study demonstrated a survival benefit of adjuvant capecitabine (adjC) for these patient groups, particularly in TNBC. Researchers have been trying to find the appropriate population for adjC as Real-World Evidence (RWE). However, RWE in the Asian population was lacking, and previous RWE studies were limited in number. In addition, these studies did not include patients who received neoadjuvant immunotherapy treatment, while the Keynote-522 trial demonstrated the benefit of immunotherapy in early TNBC. Therefore, we evaluated the advantages of adjC in non-pCR TNBC patient group by using RWD.
Methods
We conducted a retrospective analysis of 1,033 TNBC patients who received neoadjuvant treatment at Samsung Medical Center between 2018 and 2023, using de-identified, anonymous data from the institutional Clinical Data Warehouse. Among these patients, we identified 403 patients who received at least one cycle of adjC, while 36 received no adjuvant treatment. Residual Cancer Burden (RCB) classification were available for 399 patients. The primary outcome of the study was Disease-Free Survival (DFS). We conducted a survival analysis using Kaplan-Meier method.
Results
The median DFS has not yet been reached. The disease risk of the adjC group tended to be lower than that of the no adjuvant treatment group, but the difference was not statistically significant (Hazard ratio(HR), 0.52; p-value=0.083). At 36 months, 86% of patients in the adjC group were disease-free or alive, compared to 76% of patients in the no adjuvant treatment group. Compared to the RCB-I group (n=114, 28.4%), the HR for the RCB-II group (n=233, 58.5%) was 1.40, and the for the RCB-III group (n=52, 13.1%), it was 5.88 (p<0.0001). The DFS at 36 months was 90%, 89%, and 67% for the RCB-I, II, and III groups, respectively.
Conclusions
In this study, adjC demonstrated a potential survival benefit for non-pCR TNBC patients. Subgroup analysis based on RCB classification indicated a higher risk associated with higher RCB class.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This study was supported by Future Medicine 2030 Project of the Samsung Medical Center [SMO1230451].
Disclosure
M.J. Kim: Financial Interests, Personal, Full or part-time Employment: Roche Korea. Y.H. Park: Financial Interests, Personal, Advisory Board: AstraZeneca, Pfizer, Roche, Novartis, MSD, Daiichi Sankyo; Financial Interests, Personal, Invited Speaker: AstraZeneca, Pfizer, Roche, Novartis, MSD; Financial Interests, Institutional, Other, Research Grant: AstraZeneca, Pfizer, Roche, MSD; Non-Financial Interests, Principal Investigator: AstraZeneca, Pfizer, Novartis, MSD, Lilly, Roche, Daiichi Sankyo. All other authors have declared no conflicts of interest.
Resources from the same session
294P - Prognostic significance and evolution of HER2 zero, HER2 low and HER2 positive in breast cancer after neoadjuvant treatment
Presenter: Tong Wei
Session: Poster session 02
295P - ESR1, PGR, ERBB2, MKI67 single gene analysis in neoadjuvant-treated early breast cancer patients
Presenter: Rebekks Spiller
Session: Poster session 02
296P - Identification of metabolism-related therapeutic targets to improve response to neoadjuvant chemotherapy in early breast cancers
Presenter: Françoise Derouane
Session: Poster session 02
297P - Prognostic and predictive impact of NOTCH1 in early breast cancer
Presenter: Julia Engel
Session: Poster session 02
298P - Association of luminal-androgen receptor (LAR) subtype with low HER2 in triple-negative breast cancer
Presenter: Lee Min Ji
Session: Poster session 02
299P - Single-cell transcriptomic analysis reveals specific luminal and T cell subpopulations associated with response to neoadjuvant therapy in early-stage breast cancer
Presenter: Xiaoxiao Wang
Session: Poster session 02
300P - Correlation of PD-L1 protein and mRNA expression and their prognostic impact in triple-negative breast cancer
Presenter: Kathleen Schüler
Session: Poster session 02
301P - Epigenetic modifications of IL-17 gene in patients with early breast cancer and healthy controls
Presenter: Ljubica Radmilovic Varga
Session: Poster session 02
302P - Clinicopathological features and outcomes of pregnancy associated breast cancer: Case control study -single institution experience
Presenter: Nashwa Kordy
Session: Poster session 02
303P - Differential prognostic role of PDGFRA alterations in breast cancer subtypes
Presenter: Panagiotis Vlachostergios
Session: Poster session 02